Cerity Partners
CNTA

Cerity Partners’s Centessa Pharmaceuticals CNTA Stock Holding History

Cerity Partners’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-32,754
Closed -$471K – 2656
2025
Q1 		$471K Buy
+32,754
New +$536K ﹤0.01% 1788

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cerity Partners's CNTA Position: Q2 2025 in Review

Cerity Partners sold out of Centessa Pharmaceuticals (CNTA) in Q2 2025, closing a stake of 32,754 shares — an estimated $471K sold.

Cerity Partners first reported a position in CNTA in Q1 2025 and held it in 1 quarter. The position peaked at $471K in Q1 2025. 117 funds tracked by Wall St. Rank hold CNTA as of Q2 2025.

  • Cerity Partners reported no remaining Centessa Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Cerity Partners sold 32,754 Centessa Pharmaceuticals shares in Q2 2025, an estimated $471K.
  • Cerity Partners first reported a position in Centessa Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Cerity Partners's Centessa Pharmaceuticals position peaked at $471K in Q1 2025.
  • 117 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2025.

Based on Cerity Partners's 13F filing for Q2 2025, filed 13 Aug 2025.